• WKN: A14KL7
  • ISIN: DE000A14KL72
  • Land: Deutschland

Nachricht vom 13.08.2019 | 07:30

4SC AG receives milestone payment from Link Health - Link Health initiates Phase I clinical study of LH031 (4SC-205) in advanced solid malignancies or lymphoma

DGAP-News: 4SC AG / Key word(s): Alliance/Study

13.08.2019 / 07:30
The issuer is solely responsible for the content of this announcement.

4SC AG receives milestone payment from Link Health - Link Health initiates Phase I clinical study of LH031 (4SC-205) in advanced solid malignancies or lymphoma

Planegg-Martinsried, Germany, 13 August 2019 - 4SC AG (4SC, FSE Prime Standard: VSC) today announced, that it received a single digit million Euro milestone payment from its partner Guangzhou Link Health Pharma Co., Ltd (Link Health) in accordance with the licensing and development agreement for the cancer therapeutic candidate 4SC-205.

Under the 2016 agreement, Link Health received from 4SC the exclusive licensing rights for the development, regulatory submission and marketing of 4SC-205 in China, Hong Kong, Taiwan and Macao and is responsible for performing and financing the clinical development of 4SC-205.

Yan Song, Ph.D., CEO of Link Health, says: "We initiated a Phase I, open label, dose escalation trial to assess the safety, tolerability and pharmacokinetics of LH031 (4SC-205) orally administered in adult patients with advanced solid malignancies or lymphoma. Secondary objectives include to assess the drug candidate's potential anti-cancer activity."

Jason Loveridge, Ph.D., CEO of 4SC, comments: "We are very pleased that our Chinese partner has successfully advanced 4SC-205 into the next stage of development and initiated the first clinical trial with our drug candidate in Asia. 4SC remains focused on advancing our core drug candidates resminostat and domatinostat, but nonetheless our strategy to monetize and advance non-core assets through partnerships continues to progress well."

- Press release ends -


Further information

About 4SC

4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. 4SC's pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development: resminostat and domatinostat.

4SC aims to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies and/or the eventual marketing and sales of approved drugs in select territories by 4SC itself.

4SC is headquartered in Planegg-Martinsried near Munich, Germany. The Company had 47 employees as of 30 June 2019 and is listed on the Prime Standard of the Frankfurt Stock Exchange (FSE Prime Standard: VSC; ISIN: DE000A14KL72).

About Link Health

Link Health is a biopharmaceutical company developing innovative medicine for unmet medical needs. It has a drug development pipeline of 5 clinical stage assets and 1 product under NDA review in China. Headquartered in China, Link Health has a European office in the Netherlands to further strengthen the collaborations with global biopharmaceutical companies and research institutes.

More information can be found at: www.healthinlink.com.

About 4SC-205

4SC-205 is an anti-cancer compound that inhibits the kinesin spindle protein Eg5 (KIF11) which plays a key role in cancer cell division and growth. Cell division inhibitors are effective against cancers but have serious side effects on the peripheral nervous system. This type of adverse reactions does not play a significant role with 4SC-205 however.

To the best of 4SC's knowledge, 4SC-205 is the only orally available Eg5 inhibitor currently in clinical development. 4SC-205 is administered daily in low oral doses to ensure the substance is steadily available in the body and can have a continuous effect. The effectiveness of 4SC-205 against cancer cells has been confirmed in various preclinical studies. In the Phase I AEGIS study, the substance was shown to be tolerated; initial indications of efficacy have crystallized in this study as well.

The molecule has been licensed to Link Health for development in China, Hong Kong, Taiwan and Macao. 4SC can use Link Health's findings to pursue the further development of 4SC-205 in other parts of the world as well, potentially also through additional independent partnerships.

Forward-looking information

Information set forth in this press release contains forward-looking statements, which involve risks and uncertainties. The forward-looking statements contained herein represent the judgement of 4SC as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond 4SC's control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. 4SC expressly disclaims any obligation or undertaking to release any updates or revisions to any such statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.



+49 89 700763-0

13.08.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

show this

Interview im Fokus

Mountain Alliance: „Großer Digitalisierungsschub“

Furioses Börsendebüt für den Datenbankspezialisten Exasol. Einer der Profiteure: Die Münchner Beteiligungsgesellschaft Mountain Alliance AG (MA, ISIN DE000A12UK08), die auch nach einem Teilexit noch rund 2% an Exasol hält. Aktuell notiert die MA-Aktie rund 30 % unter dem NAV. Financial.de sprach mit MA-CEO Daniel Wild über die stärksten Digitalisierungstrends, die kritische Größe von 100 Mio. Euro Börsenwert, den neuen Investor und weitere Aktienkäufe.


Aves One AG: Kursziel 13,60 €

Die Aves One AG ist auch in der Corona-Krise als Bestandshalter von langlebigen Logistik-Assets mit langfristigen Mietverträgen gut aufgestellt. Das Unternehmen hat als Guidance einen Umsatz und ein EBITDA mindestens auf Vorjahresniveau verkündet. Unseres Erachtens sollte dies auch ohne Zukäufe gut machbar sein, da die im abgelaufenen Geschäftsjahr 2019 erworbenen Assets bereits zu einer höheren Umsatzbasis führen sollten. Auf Basis unseres DCF-Modells haben wir ein Kursziel in Höhe von 13,60 € ermittelt und vergeben ein KAUFEN-Rating.

News im Fokus

Vonovia SE: Vonovia veröffentlicht Nachhaltigkeitsbericht: Wohnungsunternehmen wird Vorreiter bei Erforschung effizienter Technologien (News mit Zusatzmaterial)

04. Juni 2020, 11:00

Aktuelle Research-Studie

Hawesko Holding AG

Original-Research: Hawesko Holding AG (von GSC Research GmbH): Kaufen

05. Juni 2020